<p>RIA Advisory Group LLC 在最近向证券交易委员会（SEC）披露的信息中表示，在第四季度将其在 Kodiak Sciences Inc.（NASDAQ:KOD - 免费报告）的持股减少了 31.9%。该机构投资者在此期间出售了 53,061 股后，持有该公司 113,473 股股票。Kodiak Sciences 大约占 RIA Advisory Group LLC 持有的资产的 0.8%，使其成为该公司第 24 大持股。截止最近报告期末，RIA Advisory Group LLC 持有的 Kodiak Sciences 价值约为 3,173,000 美元，占其总资产的约 0.21%。</p>
<p>获取 <strong>Kodiak Sciences</strong> 警报：</p>
<p>其他机构投资者也对该公司的持股进行了调整。GF Fund Management CO. LTD. 在第四季度购买了 Kodiak Sciences 的新股份，价值约为 29,000 美元。Mirae Asset Global Investments Co. Ltd. 在第四季度购买了 Kodiak Sciences 的新股份，价值约为 72,000 美元。Strs Ohio 在第四季度收购了 Kodiak Sciences 的新股份，价值约为 87,000 美元。BNP Paribas Financial Markets 在第三季度将其在 Kodiak Sciences 的持股增加了 89.4%。BNP Paribas Financial Markets 目前持有该公司 6,373 股股票，价值 104,000 美元，此前在此期间又购买了 3,009 股。最后，Diversified Trust Co. 在第四季度收购了 Kodiak Sciences 的新股份，价值约为 219,000 美元。89.06% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>Kodiak Sciences 股票表现</h2>
<p>KOD 股票在周五开盘价为 43.96 美元。该股票的市值为 27.3 亿美元，市盈率为 -10.18，贝塔值为 2.32。该公司有 50 日简单移动平均线为 33.92 美元，200 日简单移动平均线为 26.88 美元。Kodiak Sciences Inc. 的 52 周最低价为 2.81 美元，52 周最高价为 47.84 美元。</p>
<p>Kodiak Sciences（NASDAQ:KOD - 获取免费报告）最近于 3 月 31 日（星期二）发布了其财报。该公司报告每股收益（EPS）为 -1.04 美元，低于分析师一致预期的 -1.02 美元，差距为 -0.02 美元。卖方分析师预测 Kodiak Sciences Inc. 在当前年度将发布 -3.65 的每股收益。</p>
<h2>分析师评级调整</h2>
<p>KOD 曾是多份研究报告的主题。瑞银集团在 3 月 27 日的报告中将 Kodiak Sciences 的目标股价从 50.00 美元上调至 80.00 美元，并给予该股票 &#34;买入&#34; 评级。HC Wainwright 在 3 月 27 日的报告中重申了 &#34;买入&#34; 评级，并将 Kodiak Sciences 的目标股价设定为 58.00 美元（上调自 38.00 美元）。最后，Weiss Ratings 在 1 月 22 日的报告中重申了对 Kodiak Sciences 的 &#34;卖出（e+）&#34; 评级。五位股票研究分析师对该股票给予了买入评级，两位给予了持有评级，一位给予了卖出评级。根据 MarketBeat 的数据，Kodiak Sciences 目前的平均评级为 &#34;适度买入&#34;，平均目标价格为 35.43 美元。</p>
<p><strong>阅读我们关于 KOD 的最新股票报告</strong></p>
<h2>Kodiak Sciences 公司简介</h2>
<p>（免费报告）</p>
<p>Kodiak Sciences, Inc 是一家总部位于加利福尼亚州帕洛阿尔托的临床阶段生物制药公司，专注于发现和开发治疗视网膜疾病的新疗法。该公司的专有技术集中在抗体生物聚合物结合物（ABCs）上，旨在延长耐久性、增强组织渗透性并改善现有治疗方式的安全性。Kodiak 的研发工作针对湿性年龄相关性黄斑变性（湿性 AMD）、糖尿病性黄斑水肿（DME）和其他严重的眼科疾病。</p>
<p>Kodiak 管道中的主要产品候选是 KSI-301，一种通过玻璃体内注射给药的抗 VEGF 抗体生物聚合物结合物。</p>
<h2>精选文章</h2>
<ul>
<li>我们更看好的五只股票超过 Kodiak Sciences</li>
</ul>
<p><strong>想看看其他对冲基金持有哪些 KOD 吗？</strong> 访问 HoldingsChannel.com 获取 Kodiak Sciences Inc.（NASDAQ:KOD - 免费报告）的最新 13F 文件和内部交易。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9S09E?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9S09E"/></p>
<p><em>此即时新闻警报由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Kodiak Sciences 吗？</h2>
<p>在考虑 Kodiak Sciences 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买... 而 Kodiak Sciences 并不在名单上。</p>
<p>虽然 Kodiak Sciences 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

<p>RIA Advisory Group LLC 在第四季度减少了对 Kodiak Sciences Inc. (NASDAQ:KOD) 的持股比例，下降了 31.9%，目前持有 113,473 股。其他机构投资者也调整了他们的持仓，其中 GF Fund Management 和 Mirae Asset Global Investments 有显著的新投资。Kodiak Sciences 的股票开盘价为 43.96 美元，市值为 27.3 亿美元。该公司报告了上一季度每股亏损 1.04 美元，未能达到预期。分析师的评级各不相同，平均目标价为 35.43 美元，评级为 “适度买入”</p>

<p>RIA Advisory Group LLC reduced its position in Kodiak Sciences Inc. (NASDAQ:KOD - Free Report) by 31.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 113,473 shares of the company's stock after selling 53,061 shares during the period. Kodiak Sciences comprises approximately 0.8% of RIA Advisory Group LLC's holdings, making the stock its 24th largest position. RIA Advisory Group LLC owned approximately 0.21% of Kodiak Sciences worth $3,173,000 at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>RIA Advisory Group LLC 在最近向证券交易委员会（SEC）披露的信息中表示，在第四季度将其在 Kodiak Sciences Inc.（NASDAQ:KOD - 免费报告）的持股减少了 31.9%。该机构投资者在此期间出售了 53,061 股后，持有该公司 113,473 股股票。Kodiak Sciences 大约占 RIA Advisory Group LLC 持有的资产的 0.8%，使其成为该公司第 24 大持股。截止最近报告期末，RIA Advisory Group LLC 持有的 Kodiak Sciences 价值约为 3,173,000 美元，占其总资产的约 0.21%。</p>
</div><p>Get <strong>Kodiak Sciences</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Kodiak Sciences</strong> 警报：</p>
</div><p>Other institutional investors have also made changes to their positions in the company. GF Fund Management CO. LTD. purchased a new position in shares of Kodiak Sciences in the fourth quarter worth approximately $29,000. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Kodiak Sciences in the fourth quarter worth approximately $72,000. Strs Ohio acquired a new stake in shares of Kodiak Sciences during the fourth quarter worth approximately $87,000. BNP Paribas Financial Markets boosted its holdings in shares of Kodiak Sciences by 89.4% during the third quarter. BNP Paribas Financial Markets now owns 6,373 shares of the company's stock worth $104,000 after purchasing an additional 3,009 shares during the period. Finally, Diversified Trust Co. acquired a new stake in shares of Kodiak Sciences during the fourth quarter worth approximately $219,000. 89.06% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>其他机构投资者也对该公司的持股进行了调整。GF Fund Management CO. LTD. 在第四季度购买了 Kodiak Sciences 的新股份，价值约为 29,000 美元。Mirae Asset Global Investments Co. Ltd. 在第四季度购买了 Kodiak Sciences 的新股份，价值约为 72,000 美元。Strs Ohio 在第四季度收购了 Kodiak Sciences 的新股份，价值约为 87,000 美元。BNP Paribas Financial Markets 在第三季度将其在 Kodiak Sciences 的持股增加了 89.4%。BNP Paribas Financial Markets 目前持有该公司 6,373 股股票，价值 104,000 美元，此前在此期间又购买了 3,009 股。最后，Diversified Trust Co. 在第四季度收购了 Kodiak Sciences 的新股份，价值约为 219,000 美元。89.06% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>Kodiak Sciences Stock Performance</h2>
<div class="lb-trans"><h2>Kodiak Sciences 股票表现</h2>
</div><p>KOD stock opened at $43.96 on Friday. The stock has a market cap of $2.73 billion, a P/E ratio of -10.18 and a beta of 2.32. The firm has a 50 day simple moving average of $33.92 and a 200 day simple moving average of $26.88. Kodiak Sciences Inc. has a 52 week low of $2.81 and a 52 week high of $47.84.</p>
<div class="lb-trans"><p>KOD 股票在周五开盘价为 43.96 美元。该股票的市值为 27.3 亿美元，市盈率为 -10.18，贝塔值为 2.32。该公司有 50 日简单移动平均线为 33.92 美元，200 日简单移动平均线为 26.88 美元。Kodiak Sciences Inc. 的 52 周最低价为 2.81 美元，52 周最高价为 47.84 美元。</p>
</div><p>Kodiak Sciences (NASDAQ:KOD - Get Free Report) last posted its earnings results on Tuesday, March 31st. The company reported ($1.04) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.02) by ($0.02). Sell-side analysts predict that Kodiak Sciences Inc. will post -3.65 EPS for the current year.</p>
<div class="lb-trans"><p>Kodiak Sciences（NASDAQ:KOD - 获取免费报告）最近于 3 月 31 日（星期二）发布了其财报。该公司报告每股收益（EPS）为 -1.04 美元，低于分析师一致预期的 -1.02 美元，差距为 -0.02 美元。卖方分析师预测 Kodiak Sciences Inc. 在当前年度将发布 -3.65 的每股收益。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级调整</h2>
</div><p>KOD has been the subject of several research reports. UBS Group raised their price target on shares of Kodiak Sciences from $50.00 to $80.00 and gave the stock a &#34;buy&#34; rating in a report on Friday, March 27th. HC Wainwright restated a &#34;buy&#34; rating and set a $58.00 price target (up from $38.00) on shares of Kodiak Sciences in a report on Friday, March 27th. Finally, Weiss Ratings restated a &#34;sell (e+)&#34; rating on shares of Kodiak Sciences in a report on Thursday, January 22nd. Five equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, Kodiak Sciences currently has an average rating of &#34;Moderate Buy&#34; and an average target price of $35.43.</p>
<div class="lb-trans"><p>KOD 曾是多份研究报告的主题。瑞银集团在 3 月 27 日的报告中将 Kodiak Sciences 的目标股价从 50.00 美元上调至 80.00 美元，并给予该股票 &#34;买入&#34; 评级。HC Wainwright 在 3 月 27 日的报告中重申了 &#34;买入&#34; 评级，并将 Kodiak Sciences 的目标股价设定为 58.00 美元（上调自 38.00 美元）。最后，Weiss Ratings 在 1 月 22 日的报告中重申了对 Kodiak Sciences 的 &#34;卖出（e+）&#34; 评级。五位股票研究分析师对该股票给予了买入评级，两位给予了持有评级，一位给予了卖出评级。根据 MarketBeat 的数据，Kodiak Sciences 目前的平均评级为 &#34;适度买入&#34;，平均目标价格为 35.43 美元。</p>
</div><p><strong>Read Our Latest Stock Report on KOD</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 KOD 的最新股票报告</strong></p>
</div><h2>Kodiak Sciences Profile</h2>
<div class="lb-trans"><h2>Kodiak Sciences 公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Kodiak Sciences, Inc is a clinical‐stage biopharmaceutical company headquartered in Palo Alto, California, that focuses on the discovery and development of novel therapies for retinal diseases. The company's proprietary technology centers on antibody biopolymer conjugates (ABCs), which are designed to extend durability, enhance tissue penetration and improve the safety profile of existing therapeutic modalities. Kodiak's research and development efforts target conditions such as wet age-related macular degeneration (wet AMD), diabetic macular edema (DME) and other serious ophthalmic disorders.</p>
<div class="lb-trans"><p>Kodiak Sciences, Inc 是一家总部位于加利福尼亚州帕洛阿尔托的临床阶段生物制药公司，专注于发现和开发治疗视网膜疾病的新疗法。该公司的专有技术集中在抗体生物聚合物结合物（ABCs）上，旨在延长耐久性、增强组织渗透性并改善现有治疗方式的安全性。Kodiak 的研发工作针对湿性年龄相关性黄斑变性（湿性 AMD）、糖尿病性黄斑水肿（DME）和其他严重的眼科疾病。</p>
</div><p>The lead product candidate in Kodiak's pipeline is KSI-301, an anti-VEGF antibody biopolymer conjugate administered via intravitreal injection.</p>
<div class="lb-trans"><p>Kodiak 管道中的主要产品候选是 KSI-301，一种通过玻璃体内注射给药的抗 VEGF 抗体生物聚合物结合物。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Kodiak Sciences</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票超过 Kodiak Sciences</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding KOD?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kodiak Sciences Inc. (NASDAQ:KOD - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对冲基金持有哪些 KOD 吗？</strong> 访问 HoldingsChannel.com 获取 Kodiak Sciences Inc.（NASDAQ:KOD - 免费报告）的最新 13F 文件和内部交易。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9S09E" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=KOD"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻警报由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Kodiak Sciences Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Kodiak Sciences 吗？</h2>
</div><p>Before you consider Kodiak Sciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Kodiak Sciences 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kodiak Sciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买... 而 Kodiak Sciences 并不在名单上。</p>
</div><p>While Kodiak Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Kodiak Sciences 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

RIA Advisory Group LLC 减少了对 Kodiak Sciences Inc. $KOD 的股票持有量